Treatment of melasma

Journal of the American Academy of Dermatology

Volumn 54, Issue 5 SUPPL. 2, 2006, Pages

  Rendon, Marta ^a   Berneburg, Mark ^b   Arellano, Ivonne ^c   Picardo, Mauro ^d  

^a Dermatology and Aesthetic Center   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

^d SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ARCTOSTAPHYLOS UVA URSI EXTRACT; ASCORBIC ACID; AZELAIC ACID; CLOBETASOL PROPIONATE; DEXAMETHASONE; FLUOCINONIDE; GLYCOLIC ACID DERIVATIVE; HYDROCORTISONE; HYDROQUINONE; HYDROQUINONE PLUS GLYCOLIC ACID; HYDROQUINONE PLUS RETINOIC ACID PLUS DEXAMETHASONE; HYDROQUINONE PLUS RETINOIC ACID PLUS FLUOCINOLONE ACETONIDE; HYDROQUINONE PLUS RETINOIC ACID PLUS HYDROCORTISONE; ISOTRETINOIN; KOJIC ACID; N ACETYL 4 S CYSTEAMINYLPHENOL; PHENOL DERIVATIVE; RETINOIC ACID; UNCLASSIFIED DRUG;

APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; BURNING SENSATION; CHLOASMA; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CONTACT DERMATITIS; DRUG ERUPTION; DRY SKIN; ERYTHEMA; GRAPEFRUIT JUICE; HUMAN; IONTOPHORESIS; IRRITANT DERMATITIS; LOW LEVEL LASER THERAPY; MEDLINE; NAIL; NAIL BLEACHING; NAIL DISEASE; OCHRONOSIS; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SKIN ATROPHY; SKIN EXFOLIATION; SKIN MANIFESTATION; SKIN PAIN; SKIN PIGMENTATION; SKIN SCALING; MELANOSIS; REVIEW;

HUMANS; MELANOSIS;

EID: 33645910836     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.12.039     Document Type: Article

References (45)

1. Palumbo A., d'Ischia M., Misuraca G., and Prota G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochem Biophys Acta 1073 (1991) 85-90
2. Ennes S.B.P., Paschoalick R.C., and Mota De Avelar Alchorne M. A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. J Dermatolog Treat 11 (2000) 173-179
3. Haddad A.L., Matos L.F., Brunstein F., Ferreira L.M., Silva A., and Costa D. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int J Dermatol 42 (2003) 153-156
4. Ferreira Cestari T, Hassun K, Sittart A, de Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma [abstract P2605]. Presented as a poster at the 63rd Annual Meeting of the American Academy of Dermatology, New Orleans, La. Feb 18-22, 2005.
5. Romero C., Aberdam E., Larnier C., and Ortonne J.P. Retinoic acid as modulator of UVB-induced melanocyte differentiation. Involvement of the melanogenic enzymes expression. J Cell Sci 107 (1994) 1095-1103
6. Kimbrough-Green C.K., Griffiths C.E., Finkel L.J., Hamilton T.A., Bulengo-Ransby S.M., Ellis C.N., et al. Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol 130 (1994) 727-733
7. Griffiths C.E., Finkel L.J., Ditre C.M., Hamilton T.A., Ellis C.N., and Voorhees J.J. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol 129 (1993) 415-421
8. Leenutaphong V., Nettakul A., and Rattanasuwon P. Topical isotretinoin for melasma in Thai patients: a vehicle-controlled clinical trial. J Med Assoc Thai 82 (1999) 868-875
9. Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol 39 Suppl (1998) S17-S24
10. Dogra S., Kanwar A.J., and Parasad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol 29 (2002) 539-540
11. Fitton A., and Goa K.L. Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 41 (1991) 780-798
12. Rigoni C., Toffolo P., Serri R., and Caputo R. [Use of a cream based on 20% azelaic acid in the treatment of melasma]. G Ital Dermatol Venereol 124 (1989) I-VI. Italian
13. Verallo-Rowell V.M., Verallo V., Graupe K., Lopez-Villafuerte L., and Garcia-Lopez M. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh) 143 (1989) 58-61
14. Balina L.M., and Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 30 (1991) 893-895
15. Zaumseil R.-P., and Graupe K. Topical azelaic acid in the treatment of melasma: pharmacological and clinical considerations. Melasma - New approaches to therapy (1995), Martin-Dunitz, London 19-41
16. Sarkar R., Bhalla M., and Kanwar A.J. A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology 205 (2002) 249-254
17. Ros J.R., Rodriguez-Lopez J.N., and Garcia-Canovas F. Effect of L-ascorbic acid on the monophenolase activity of tyrosinase. Biochem J 295 (1993) 309-312
18. Huh C.-H., Seo K.-I., Park J.-Y., Lim J.-G., Eun H.-C., and Pak K.-C. A randomized, double-blind, placebo-controlled trail of vitamin C iontophoresis in melasma. Dermatology 206 (2003) 316-320
19. Jimbow K. N-acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma. Arch Dermatol 127 (1991) 1528-1534
20. Yoshimura K., Harii K., Aoyama T., and Iga T. Experience with a strong bleaching treatment for skin hyperpigmentation in Orientals. Plast Reconstr Surg 105 (2000) 1097-1108
21. Kauh Y.C., and Zachian T.F. Melasma. Adv Exp Med Biol 455 (1999) 491-499
22. Guevara I.L., and Pandya A.G. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol 42 (2003) 966-972
23. Lim J.T. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg 25 (1999) 282-284
24. Garcia A., and Fulton J.E. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg 22 (1996) 443-447
25. Kligman A.M., and Willis I. A new formula for depigmenting human skin. Arch Dermatol 111 (1975) 40-48
26. Taylor S.C., Torok H., Jones T., Lowe N., Rich P., Tschen E., et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 72 (2003) 67-72
27. Torok H.M., Jones T., Rich P., Smith S., and Tschen E. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis 75 (2005) 57-62
28. Taylor SC, Torok H, Jones T. Lowe V. Long-term (12 month) safety and efficacy of triple combination agent (4% hydroquinone + 0.05% tretinoin + 0.01% fluocinolone acetonide) in the treatment of patients with melasma of the face [abstract P234]. Presented as a poster at the 63rd Annual Meeting of the American Academy of Dermatology, New Orleans, La, Feb 18-21, 2005.
29. Galderma International. Data on file. March 8, 2006.
30. Sarkar R., Kaur C., Bhalla M., and Kanwar A.J. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg 28 (2002) 828-832
31. Kang W.H., Chun S.C., and Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies. J Dermatol 25 (1998) 587-596
32. Javaheri S.M., Handa S., Kaur I., and Kumar B. Safety and efficacy of glycolic acid facial peel in Indian women with melasma. Int J Dermatol 40 (2001) 354-357
33. Lawrence N., Cox S.E., and Brody H.J. Treatment of melasma with Jessner's solution versus glycolic acid: a comparison of clinical efficacy and evaluation of the predictive ability of Wood's light examination. J Am Acad Dermatol 36 (1997) 589-593
34. Hurley M.E., Guevara I.L., Gonzales R.M., and Pandya A.G. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol 138 (2002) 1578-1582
35. Lim J.T.E., and Tham S.N. Glycolic acid peels in the treatment of melasma among Asian women. Dermatol Surg 23 (1997) 177-179
36. Grimes P.E. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg 25 (1999) 18-22
37. Cucé L.C., Bertino M.C., Scattone L.K., and Birkenhauer M.C. Tretinoin peeling. Dermatol Surg 27 (2001) 12-14
38. Cotellessa C., Peris K., Onorati M.T., Fargnoli M.C., and Chimenti S. The use of chemical peelings in the treatment of different cutaneous hyperpigmentations. Dermatol Surg 25 (1999) 450-454
39. Kopera D., and Hohenleutner U. Ruby laser treatment of melasma and postinflammatory hyperpigmentation. Dermatol Surg 21 (1995) 990-995
40. 2 laser followed by Q-switched alexandrite laser: a pilot study. Dematol Surg 25 (1999) 494-497
41. 2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma: split-faced design. Dermatol Surg 29 (2003) 59-64
42. Lee G.-Y., Kim H.-J., and Whang K.-K. The effect of combination treatment of the recalcitrant pigmentary disorders with pigmented laser and chemical peeling agent. Dermatol Surg 28 (2002) 1120-1123
43. Manaloto R.M., and Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg 25 (1999) 121-123
44. Kunachak S., Leelaudomlipi P., and Wongwaisayawan S. Dermabrasion: a curative treatment for melasma. Aesthetic Plast Surg 25 (2001) 114-117
45. Williams H.C. Dermatology. In: Stevens A., and Raferty J. (Eds). Health care needs assessment. Second series (1997), Radcliffe Medical Press, New York 340